Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye test may predict brain decline in heart patients

NCT ID NCT07607756

Knowledge-focused Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study looks at whether a simple, non-invasive eye scan (OCT-A) can detect early signs of memory decline in people with atrial fibrillation, a common heart rhythm disorder. Researchers will compare retinal blood vessel patterns in 40 patients with and without mild cognitive impairment. The goal is to see if the retina, often called a 'window to the brain,' could become a practical screening tool for cognitive decline in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward a simple, non-invasive eye scan to help identify early memory problems in people with atrial fibrillation.
What could go wrong
This is a small, early pilot study with only 40 participants, so results may not apply to everyone. It is designed to test feasibility, not to prove a screening tool works yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \> 40 years old * AF confirmed by cardiologist * signed informed consent Exclusion Criteria: * history of stroke or thromboembolic event * recent history of ocular surgery * ocular diseases (severe cataract, glaucoma, macular degeneration, corneal ulcer, optic neuropathies) * history of any systemic illness that may impact structure and microvasculature of the retina such as diabetes, hyperthyroidism, rheumatic disease, severe kidney injury, liver failure, advanced malignancy, * OCT-A images of insufficient quality (due to artifacts) * history of AF ablation * major depression or other psychiatric/ neurodegenerative disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Mild cognitive impairment Oct angiography

Contacts and locations

Locations

  • UZ Brussel

    Jette, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.